{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=77",
    "query": {
      "condition": "Lymphoma",
      "page": 77
    },
    "page_size": 10
  },
  "pagination": {
    "page": 77,
    "page_size": 10,
    "total_count": 5758,
    "total_pages": 576,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=78&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=76&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T10:24:53.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05377827",
      "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-Cell Non-Hodgkin Lymphoma",
        "Acute Myeloid Leukemia",
        "Angioimmunoblastic T-cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma",
        "Peripheral T Cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Adult T Cell Leukemia",
        "Adult T Cell Lymphoma",
        "T Cell Prolymphocytic Leukemia",
        "Extranodal NK/T-cell Lymphoma",
        "Transformed Mycosis Fungoides",
        "Sezary Syndrome",
        "Primary Cutaneous Gamma-Delta T-Cell Lymphoma",
        "Hepatosplenic T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "WU-CART-007",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-10-10",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377827"
    },
    {
      "nct_id": "NCT04980222",
      "title": "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2022-03-22",
      "completion_date": "2026-10-15",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Stanford, California • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980222"
    },
    {
      "nct_id": "NCT03862131",
      "title": "PROactive Evaluation of Function to Avoid CardioToxicity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiotoxicity",
        "Breast Cancer",
        "Lymphoma",
        "Sarcoma",
        "Leukemia",
        "Myeloma",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "MyoStrain®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2019-03-13",
      "completion_date": "2024-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03862131"
    },
    {
      "nct_id": "NCT01476839",
      "title": "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adult Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "basiliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "yttrium Y 90-labeled basiliximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2013-02-13",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01476839"
    },
    {
      "nct_id": "NCT01206777",
      "title": "Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Indolent or Intermediate Grade B-cell Malignancy"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-10",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-20",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01206777"
    },
    {
      "nct_id": "NCT05621096",
      "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "DLBCL - Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Follicular Lymphoma",
        "Mediastinal Large B-cell Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bridging radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Liso-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Post-infusion radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-03-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05621096"
    },
    {
      "nct_id": "NCT00516503",
      "title": "Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neurotoxicity",
        "Pain",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "baclofen/amitriptyline/ketamine gel",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2008-02",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 165,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Aurora",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516503"
    },
    {
      "nct_id": "NCT00569842",
      "title": "Investigation of the Cylex® ImmuKnow® Assay",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia",
        "Non-Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Hodgkin's Disease",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Disorders",
        "Aplastic Anemia",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2007-11",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2014-09-11",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00569842"
    },
    {
      "nct_id": "NCT00939770",
      "title": "Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 122,
      "start_date": "2009-09-21",
      "completion_date": "2018-12-31",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939770"
    },
    {
      "nct_id": "NCT01796470",
      "title": "Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "Indolent Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Entospletinib",
          "type": "DRUG"
        },
        {
          "name": "Idelalisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2013-06-20",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2020-06-02",
      "last_synced_at": "2026-11-02T10:24:53.813Z",
      "location_count": 13,
      "location_summary": "La Jolla, California • Long Beach, California • Oxnard, California + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01796470"
    }
  ]
}